PCR Journal Club

The present study aimed to revise the IVUS-derived segmental MSA criteria for optimal stent expansion in patients undergoing an up-front 2-stent strategy using the crush technique for LM bifurcation lesions to predict the 5-year clinical outcomes.

In coronary bifurcation lesions (CBL) PCI, intracoronary imaging (ICI) is preferred for its superior outcomes over angiography alone, but its adoption is limited by education and technology access barriers, resulting in most CBL PCIs still using angiographic guidance only.

This trial found that, in ACS patients undergoing PCI, DP-DES and BP-DES had similar patient-oriented outcomes at three years, but BP-DES had higher device-oriented composite outcomes, mainly due to increased TLR risk.

The take-home message for clinicians is that in the treatment of tricuspid regurgitation, the most frequent valvular disease alongside aortic stenosis, redefining procedural success as a function of the residual degree of TR is crucial.

The results of this study show that IVUS guidance is associated with less late lumen loss compared to angiography guidance in HBR patients undergoing DCB angioplasty.

The optimal duration of short DAPT in ACS patients is unknown, therefore this analysis of the XIENCE Short DAPT programme compared the clinical outcomes of one versus three months DAPT in HBR patients with and without ACS.

This pre-specified substudy of CompareCrush aimed to examine if patients with a large myocardial infarction benefit from prehospital crushed prasugrel.

This study demonstrated, for the first time, that PPG - an index to characterize focal vs. diffuse disease - can predict optimal functional revascularization outcomes (post-PCI FFR ≥ 0.88) more accurately than FFR alone.

This analysis shows that diabetic patients undergoing revascularization face substantially higher 5-year rates of all-cause mortality, myocardial infarction, repeat revascularizations, and stroke compared to non-diabetic patients.

This study highlights the TRISCORE's role in assessing risk for patients undergoing TTVI. Despite limitations, TRISCORE effectively identifies high-risk patients, aiding decision-making in a complex landscape of valvular heart disease management.